$ALCJ (Crossject) = US government locked in $155M contract. Market has no idea.

I found a French medtech on Euronext with the only needle-free emergency injector on the market (**ZENEO®**). The US government is showing strong interest and has already signed a $155M contract. Risk/reward looks interesting enough at current prices to dig deeper. Ticker is **$ALCJ (Crossject)**. You can grab it on IBKR or any broker with Euronext access. **The problem they're solving (and why it's massive)** Standard tools like EpiPen work, but they’re old, needle‑based and require a steady hand in situations where people are panicking, seizing or in shock. **ZENEO®** is a single‑use, needle‑free auto‑injector powered by a small pyrotechnic gas generator (same principle as an airbag). You press it, it fires in under a tenth of a second through clothes (jeans, tactical gear, jackets, etc.). No need to expose the skin, no needle to aim, no manual technique. That's a game-changer for emergency response situations where you can't strip someone down or find a vein. Their most advanced product is **ZENEO®** ***ZEPIZURE*****®** (midazolam) for epileptic seizures / emergency rescue situations, but the same device concept can be used for other emergency drugs (adrenaline, naloxone, etc.). They've been developing ZENEO**®** for over 20 years. We're not talking about Phase 1 or Phase 2 speculation. The product is finalized, validated, and ready for commercialization. **Government validation: BARDA + DoD interest** In June 2022, Crossject signed a contract with **BARDA** (US Biomedical Advanced Research and Development Authority) for the Strategic National Stockpile: * Around **$60M** firm order for initial stockpile after FDA authorization * About **$32M** in development funding * Up to **$63M** in additional options if milestones are met * **Total potential value: $155M** Since then, BARDA has added more funding to support continued development and the EUA process. BARDA backing this means it's essential for national security. Most companies never get that level of validation. On top of BARDA, the **US Department of Defense** is showing real interest through a cooperation agreement with Crossject. Fast, through-clothing injections line up perfectly with battlefield/CBRN scenarios and fit their operational needs naturally. The French government has also provided support through funding like the *France 2030* plan. **Moat + market opportunity** Right now almost all emergency injectors are still needle‑based. Crossject’s angle is: * Needle‑free * Through clothing * Very fast, almost no user training needed * Remove human error They have a big patent wall (over 400 patents around the pyrotechnic injection mechanism and device design) which makes a straight copy difficult. The addressable market is substantial: epilepsy, anaphylaxis, naloxone overdoses... Billions in total across these areas. There's no real competition. Every other emergency injector out there uses needles. Crossject is the only player with proprietary needle-free technology validated for emergency use at scale. Here's what separates this from typical biotech gambling. They're solving a real emergency response problem: when seconds matter you need something that works instantly and reliably. **Catalyst: FDA EUA and final regulatory phase** The key short-/medium‑term catalyst is the **FDA Emergency Use Authorization (EUA)** for ZENEO**®** *ZEPIZURE***®**. Regulatory timelines have been long and the company has had delays like most small medtechs. That’s part of the risk. But recent communications from Crossject indicate they are in the **final regulatory phase** for the EUA filing. The FDA has demanded 99.99%+ reliability. Crossject delivered. The next expected logical “big” news from them would be confirmation that the EUA has been granted. Once the EUA is in place the initial BARDA stockpile order ($60M) gets triggered immediately for the Strategic National Stockpile. It de‑risks the tech in the eyes of other potential partners (defense, big pharma, etc.) and potentially opening acquisition interest. **Valuation vs contract** The math is simple: * Market cap is currently around **$100M** * BARDA contract potential is **$155M** You’re basically paying less than the value of the already‑signed US government framework for a company whose technology could be used across several emergency and possibly chronic indications. Most retail investors have never even heard of $ALCJ. That's exactly when alpha gets made. In a scenario where EUA is granted and execution is decent, a 2-5x valuation from current levels doesn't feel crazy over time. Add in BARDA scaling production, pipeline expansion (Adrenaline, Naloxone for overdoses, Midazolam for other emergencies,…) and you're looking at serious multi-bagger potential. **Risks (and why I still care)** Yes, there's been dilution and delays. Building breakthrough tech takes time and money. There will always be risk in biotech/medtech that's just how it works. But you're investing in a proven technology with government backing and a catalyst on the horizon. That's a solid setup. The latest company messaging is about being in the final regulatory stage with the FDA for EUA which narrows the uncertainty compared to a pure early‑stage biotech bet. **My take** I have real conviction on this one, even knowing it’s still a risky small‑cap medtech. For me the combo of: * Proven tech + very practical use case * Signed US government contract (BARDA) and DoD interest * Platform potential across multiple emergency drugs * Current valuation vs committed contract size makes it an asymmetric setup worth holding a position in. Alongside the investment returns, you're backing a device that can save lives. **NFA, DYOR.** But if you're looking for a medtech with solid fundamentals: actual tech, actual government orders, actual near-term catalysts, zero real competition. $ALCJ checks every box. I'm holding, convinced the risk/reward is asymmetric here. Anyone else watching $ALCJ? **TL;DR** * French medtech **Crossject ($ALCJ)** built **ZENEO®** a needle‑free auto‑injector that fires in under 0.1s through clothing. It can be used for adrenaline, naloxone, etc. * US government (BARDA) signed a contract with **up to $155M** in value, first stockpile order hits after FDA EUA. DoD also appears interested for defense use. * Tech is protected by a big patent portfolio and sits in a multi‑billion fast‑growing auto‑injector / needle‑free market. * Company says it’s in the **final regulatory phase** for FDA EUA. If granted, it will trigger the initial BARDA order and de‑risk the platform. * Market cap is around **$100M**, below the potential value of the existing US contract (**$155M**). If execution and regulation go right, upside could be significant though risks like delays or dilution are always part of the picture.